(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 May 2011 (05.05.2011)

PCT

(10) International Publication Number
WO 2011/053660 A3

(51) International Patent Classification:
C12N 15/63 (2006.01) *A61K 31/7105* (2006.01)
C12N 15/113 (2010.01) *A61P 35/00* (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2010/054350

(22) International Filing Date:
27 October 2010 (27.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/256,867 30 October 2009 (30.10.2009) US
12/913,515 27 October 2010 (27.10.2010) US

(71) Applicant *(for all designated States except US)*: **GRADALIS, INC.** [US/US]; 2545 Golden Bear Drive, Suite 110, Carrolton, TX 75006 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NEMUNAITIS, John, J.** [US/US]; 1136 Mallard Pointe Drive, Cedar Hill, TX 75104-6911 (US). **RAO, Donald** [US/US]; 3355 Blackburn Street, Dallas, TX 75204 (US). **BRUNICARDI, Charles, F.** [US/US]; 4036 Case Street, Houston, TX 77005 (US).

(74) Agent: **FLORES, Edwin**; Chalker Flores, LLP, 14951 North Dallas Parkway, Suite 400, Dallas, TX 75254 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,

[Continued on next page]

WO 2011/053660 A3

(54) Title: NOVEL THERAPEUTIC RNA INTERFERENCE TECHNOLOGY TARGETED TO THE PDX-1 ONCOGENE IN PDX-1 EXPRESSING NEUROENDOCRINE TUMORS




FIG. 1A




FIG. 1B

(57) Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-I oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-I oncogene.

SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
6 October 2011